Logo for Immunic Inc

Immunic Investor Relations Material

Latest events

Logo for Immunic Inc

Study Update

Immunic
Logo for Immunic

Study Update

30 Apr, 2025
Logo for Immunic

Q4 2024

30 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Immunic Inc

Access all reports
Immunic Inc. is a clinical-stage biopharmaceutical company, developing a pipeline of selective oral immunology therapies. The company’s lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. Its other programs are IMU-935 for the restoration of the intestinal barrier in patients suffering from diseases such as inflammatory bowel disease; IMU-856 for restoration of the intestinal barrier function in patients suffering from diseases such as inflammatory bowel disease with diarrhea; and an anti-inflammatory intravenous formulation being developed to treat acute kidney injury.